Follow
Edward R Scheffer Cliff, MBBS (Hons) MPH
Edward R Scheffer Cliff, MBBS (Hons) MPH
Verified email at bwh.harvard.edu - Homepage
Title
Cited by
Cited by
Year
Outcomes of patients with CLL sequentially resistant to both BCL2 and BTK inhibition
TE Lew, VS Lin, ER Cliff, P Blombery, ER Thompson, SM Handunnetti, ...
Blood Advances 5 (20), 4054-4058, 2021
462021
Neonatal diabetes caused by a homozygous KCNJ11 mutation demonstrates that tiny changes in ATP sensitivity markedly affect diabetes risk
N Vedovato, E Cliff, P Proks, V Poovazhagi, SE Flanagan, S Ellard, ...
Diabetologia, 1-7, 2016
292016
High Cost of Chimeric Antigen Receptor T-Cells: Challenges and Solutions
ERS Cliff, AH Kelkar, DA Russler-Germain, FA Tessema, AJN Raymakers, ...
American Society of Clinical Oncology Educational Book 43, e397912, 2023
162023
Acknowledging infection risk in bispecific antibody trials in the treatment of multiple myeloma
ERS Cliff, G Reynolds, R Popat, BW Teh, AS Kesselheim, GR Mohyuddin
Journal of Clinical Oncology 41 (10), 1949-1951, 2023
122023
Hypocalcaemia following denosumab in prostate cancer: A clinical review
LH Lau, ERS Cliff, V Wong, H Wong, N Torkamani, A Eer, A Weickhardt, ...
Clinical Endocrinology 92 (6), 495-502, 2020
102020
Infections following bispecific antibodies in myeloma: a systematic review and meta-analysis.
G Reynolds, ERS Cliff, GR Mohyuddin, R Popat, S Midha, M Ng Liet Hing, ...
Blood Advances, 2023
92023
Permanent neonatal diabetes: combining sulfonylureas with insulin may be an effective treatment
S Misra, N Vedovato, E Cliff, E De Franco, AT Hattersley, FM Ashcroft, ...
Diabetic Medicine 35 (9), 1291-1296, 2018
92018
T-cell replete allogeneic stem cell transplant for mantle cell lymphoma achieves durable disease control, including against TP53-mutated disease
TE Lew, ERS Cliff, M Dickinson, CS Tam, JF Seymour, P Blombery, ...
Bone Marrow Transplantation 56 (11), 2857-2859, 2021
72021
Teclistamab in Relapsed or Refractory Multiple Myeloma
ERS Cliff, H Mian, GR Mohyuddin
The New England journal of medicine 387 (18), 1721-1722, 2022
52022
Overall survival as a primary end point in multiple myeloma trials
ERS Cliff, GR Mohyuddin
Nature Reviews Clinical Oncology 19 (9), 565-566, 2022
52022
Achieving self-sufficiency: training Australia’s future medical workforce
B Fernandes, ERS Cliff, A Chowdhury
Australian Health Review, 2017
52017
Clinician preferences on treatment of smoldering myeloma: a cross-sectional survey
GR Mohyuddin, R Chakraborty, ERS Cliff, BA Derman
eClinicalMedicine 65, 2023
42023
Melflufen: post-hoc subgroup analyses and the US FDA Oncologic Drugs Advisory Committee
ERS Cliff, M Janakiram, AS Kesselheim
The Lancet Haematology 10 (5), e314-e317, 2023
42023
CARTIFAN-1: Concerning Fatal Adverse Events with Global use of Chimeric Antigen Receptor–T-Cell Therapy in Multiple Myeloma
S Al Hadidi, ERS Cliff
European Journal of Cancer, 2022
42022
Frontline polatuzumab vedotin for diffuse large B‐cell lymphoma: A survey of clinician impressions
A Major, ERS Cliff, DA Ermann, U Durani, DA Russler‐Germain
EJHaem 3 (3), 930-935, 2022
42022
Cell-of-origin effect of polatuzumab vedotin in diffuse large B-cell lymphoma: no ordinary subgroup analysis
DA Russler-Germain, ERS Cliff, NL Bartlett
Blood 142 (25), 2216-2219, 2023
32023
National Comprehensive Cancer Network Guideline Recommendations of Cancer Drugs With Accelerated Approval
ERS Cliff, RS Rome, AS Kesselheim, BN Rome
JAMA Network Open 6 (11), e2343285-e2343285, 2023
32023
Is aggressive treatment of smoldering myeloma the path to curing myeloma?
R Chakraborty, S Al Hadidi, ERS Cliff, GR Mohyuddin
Blood Advances, 2023
32023
Cost-effectiveness of Aducanumab and Donanemab for Early Alzheimer Disease—Estimating the True Value
ERS Cliff, AH Kelkar
JAMA neurology, 2022
32022
Treatment of Mantle-Cell Lymphoma
ERS Cliff, M Dickinson
The New England journal of medicine 387 (12), 1146-1148, 2022
3*2022
The system can't perform the operation now. Try again later.
Articles 1–20